Arcturus Therapeutics Holdings Stock News

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Citing data from its Phase 1/2 booster study for ARCT-154 and ARCT-165, Arcturus Therapeutics (ARCT) says that the companys self-amplifying mRNA vaccine candidates strongly

Arcturus Therapeutics <> said data from ARCT-154 and ARCT-165 booster trial showed neutralizing antibody responses to SARS-CoV-2 and several variants.Full cohort data from

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates

Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.65, but opened at $43.86. Arcturus Therapeutics shares last traded at $42.00, with a volume of 2,855 shares. ARCT has been the subject of a number of analyst reports. Barclays decreased their price []

Brokerages predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will report sales of $12.90 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Arcturus Therapeutics earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $43.40 million. Arcturus Therapeutics reported sales []

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was up 8.9% during trading on Friday . The stock traded as high as $46.88 and last traded at $46.83. Approximately 19,475 shares changed hands during trading, a decline of 98% from the average daily volume of 825,301 shares. The stock had previously closed at $43.00. Several research analysts have []

The biotech stock climbed more than $5 a share in early trading Thursday.

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying mRNA vaccine candidates for COVID-

Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.

Equities research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to report ($1.81) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics posted earnings of ($1.25) per share in the same quarter last year, which []

Brokerages expect that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will announce earnings per share (EPS) of ($1.81) for the current quarter, according to Zacks. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics reported earnings of ($1.25) per share in the same quarter last year, which indicates []

Charles Schwab Investment Management Inc. lifted its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.4% during the second quarter, Holdings Channel reports. The fund owned 144,621 shares of the biotechnology companys stock after acquiring an additional 6,095 shares during the period. Charles Schwab Investment Management Inc.s holdings in Arcturus Therapeutics were worth []